Results 21 to 30 of about 8,410,436 (169)
Onset and duration of action of lokivetmab in a canine model of IL‐31 induced pruritus
Veterinary Dermatology, Volume 32, Issue 6, Page 681-e182, December 2021., 2021 Onset of antipruritic action of lokivetmab in dogs. Laboratory‐bred beagle dogs were dosed subcutaneously with either placebo or lokivetmab at 2.0 mg/kg on Day (D) 0. Approximately 2.5 h post‐dosing, pruritus was induced using canine interleukin (IL)‐31. Animals were observed for pruritic behaviours for a total of 2 h (3–5 h post‐treatment with placebo
Timothy J. Fleck +6 more
wiley +1 more source
Veterinary Dermatology, Volume 32, Issue 5, Page 477-e131, October 2021., 2021 Background – Interleukin (IL)‐31 is an important mediator in canine atopic dermatitis (cAD) and also may be dysregulated in other allergic diseases. Hypothesis/Objectives – To demonstrate the efficacy and safety of lokivetmab (canine anti‐IL‐31 monoclonal antibody) for treatment of pruritus associated with allergic dermatitis in dogs.
Leen Van Brussel +4 more
wiley +1 more source
Treatment of equine sarcoids using recombinant poxviruses expressing feline interleukin‐2
Veterinary Dermatology, Volume 32, Issue 3, Page 283-e77, June 2021., 2021 Background – Interleukin (IL)‐2 stimulates antitumour immunity and is successfully used for the treatment of different neoplasias. Hypothesis/Objectives –Canarypox virus locally expressing feline IL‐2 is safe and can be used to treat equine sarcoids. Conclusions –Treatment of equine sarcoids with recombinant canarypox virus expressing feline IL‐2 seems
Johanna Loschelder‐Ostrowski +4 more
wiley +1 more source
Serum concentrations of IL‐31 in dogs with nonpruritic mast cell tumours or lymphoma
Veterinary Dermatology, Volume 31, Issue 6, Page 466-e124, December 2020., 2020 Background The aim of this study was to compare serum interleukin (IL)‐31 concentrations in dogs with lymphoma and mast cell tumours (MCT) without pruritus to those of healthy dogs. Hypothesis/Objectives To determine if IL‐31 plays a role in tumour pathogenesis and if IL‐31 could be a biological marker for disease progression.
Nataliia Ignatenko +8 more
wiley +1 more source
Veterinary Dermatology, Volume 31, Issue 2, Page 154-e30, April 2020., 2020 Background Thymic stromal lymphopoietin (TSLP) plays a key role in the development of allergic inflammation. Little is known about possible triggers of equine TSLP expression. Hypothesis To investigate TSLP expression in equine insect bite hypersensitivity (IBH) skin lesions.
Iva Cvitas +4 more
wiley +1 more source
Effect of maternal high-fat diet on placental phenotype in mice [PDF]
, 2023 Objective·To analyze the effects of maternal high-fat diet on placental phenotype, and investigate the role of placental microenvironment in the intergenerational transmission.Methods·The 3-week-old C57BL/6J female mice were fed with either the high-fat ...
DONG Yan +3 more
core +1 more source
Mechanism of water-soluble propolis in alleviating ulcerative colitis in rats [PDF]
, 2020 Objective To investigate the mechanism of water-soluble propolis (WSP) in relieving dextran sulfate sodium (DSS) -induced intestinal inflammation in ulcerative colitis (UC) rats. Methods SD rats were randomly divided into 5 groups: CON, DSS, L-WSP, M-WSP,
Hua ZHOU, Min ZHANG
core +1 more source
Study on the relationship between red meat, dietary Neu5Gc intake and anti-Neu5Gc antibody [PDF]
, 2015 唾液酸类化合物是以九碳糖神经氨酸(5-amino-3,5-dideoxy-D-glycero-D-galactononulsonicacid)为基本结构的一族衍生物的总称。目前，已分离和鉴定的有50余种，包括N-乙酰基神经氨酸(N-acetylneuraminicacid,Neu5Ac)、N-羟乙酰基神经氨酸(N-glycoulylneuraminicacid,Neu5Gc)和2－酮基－3－脱氧九酮糖酸(2-keto-3-deoxy-nonulosonicacid,KDN)三种核心单体 ...
范杏丹
core
Research progress in the effect of nutritional intervention on cognitive impairment related to Alzheimer's disease [PDF]
, 2023 Alzheimer's disease (AD) is an age-related neurodegenerative disease with insidious onset and slow progression. The progression of AD from only brain pathological changes to clinically identifiable cognitive changes is affected by a variety of ...
HUANG Gaozhong, JIANG Xinting
core +1 more source
Long‐term use of lokivetmab in dogs with atopic dermatitis
Veterinary Dermatology, Volume 35, Issue 6, Page 683-693, December 2024.Background – Lokivetmab, a caninised monoclonal antibody against interleukin (IL)‐31, is an effective treatment for the pruritus associated with canine atopic dermatitis (cAD). Objectives – To investigate the efficacy and safety of lokivetmab during long‐term treatment defined as at least three consecutive lokivetmab injections in atopic dogs under ...
Bettina Kasper +2 more
wiley +1 more source